Skip to main content
Top
Published in: The International Journal of Cardiovascular Imaging 4/2017

Open Access 01-04-2017 | Original Paper

Comparative assessment of “plaque/media” change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study

Authors: Yaping Zeng, Rafael Cavalcante, Erhan Tenekecioglu, Pannipa Suwannasom, Yohei Sotomi, Carlos Collet, Mahammad Abdelghani, Hans Jonker, Franck Digne, Dieter Horstkotte, Manfred Zehender, Ciro Indolfi, Francesco Saia, Rosario Fiorilli, Bernard Chevalier, Leonardo Bolognese, Javier Goicolea, Shaoping Nie, Yoshinobu Onuma, Patrick W. Serruys, On behalf of the investigators of Absorb II study

Published in: The International Journal of Cardiovascular Imaging | Issue 4/2017

Login to get access

Abstract

The purpose of the study to assess the comparability of immediate changes in plaque/media volume (PV) on three modalities of intravascular ultrasound (IVUS) after implantation of either bioresorbable vascular scaffold (BVS) or everolimus-eluting metallic stent (EES) in Absorb II Study. The two devices have different device volume and ultrasound backscattering that may interfere with the “plaque/media” assessed by three modalities on IVUS: grayscale, backscattering of radiofrequency and brightness function. In a multicenter randomized controlled trial, 501 patients with stable or unstable angina underwent documentary IVUS pre- and post- implantation. The change in plaque/media volume (PV) was categorized into three groups according to the relative PV change in device segment: PV “increased” >+5% (PVI), PV unchanged ±5% (PVU), and PV decreased <−5% (PVD). The change in PV was re-evaluated three times: after subtraction of theoretical device volume, after analysis of echogenicity based on brightness function. In 449 patients, 483 lesions were analyzed pre- and post-implantation. “PVI” was more frequently observed in BVS (53.8%) than EES group (39.4%), p = 0.006. After subtraction of the theoretical device volume, the frequency of “PVI” decreased in both BVS (36.2%) and EES (32.1%) groups and became comparable (p = 0.581). In addition, the percentage of “PVI” was further reduced in both device groups after correction for either radiofrequency backscattering (BVS 34.4% vs. EES 22.6%) or echogenicity (BVS 25.2% vs. EES 9.7%). PV change in device segment was differently affected by BVS and EES devices implantation due to their differences in device volume and ultrasound backscattering. It implies that the lumen volume was also artifactually affected by the type of device implanted. Comparative IVUS assessment of lumen and plaque/media volume changes following implantation of BVS and EES requires specific methodological adjustment.
Literature
1.
go back to reference Nicholls SJ et al (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365(22):2078–2087CrossRefPubMed Nicholls SJ et al (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365(22):2078–2087CrossRefPubMed
2.
go back to reference Bourantas CV et al (2013) Clinical and angiographic characteristics of patients likely to have vulnerable plaques: analysis from the PROSPECT study. JACC Cardiovasc Imaging 6(12):1263–1272CrossRefPubMed Bourantas CV et al (2013) Clinical and angiographic characteristics of patients likely to have vulnerable plaques: analysis from the PROSPECT study. JACC Cardiovasc Imaging 6(12):1263–1272CrossRefPubMed
3.
go back to reference Mintz GS et al (2001) American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol 37(5):1478–1492CrossRefPubMed Mintz GS et al (2001) American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol 37(5):1478–1492CrossRefPubMed
4.
go back to reference Wong M et al (1993) Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. Arterioscler Thromb 13(4):482–486CrossRefPubMed Wong M et al (1993) Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. Arterioscler Thromb 13(4):482–486CrossRefPubMed
5.
go back to reference Serruys PW et al (2014) Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 9(11):1271–1284CrossRefPubMed Serruys PW et al (2014) Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 9(11):1271–1284CrossRefPubMed
6.
go back to reference Serruys PW et al (2015) A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385(9962):43–54CrossRefPubMed Serruys PW et al (2015) A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385(9962):43–54CrossRefPubMed
7.
go back to reference Diletti R et al (2012) ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 164(5):654–663CrossRefPubMed Diletti R et al (2012) ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 164(5):654–663CrossRefPubMed
8.
go back to reference Papadopoulou SL et al (2012) Natural history of coronary atherosclerosis by multislice computed tomography. JACC Cardiovasc Imaging 5(3 Suppl):S28–S37CrossRefPubMed Papadopoulou SL et al (2012) Natural history of coronary atherosclerosis by multislice computed tomography. JACC Cardiovasc Imaging 5(3 Suppl):S28–S37CrossRefPubMed
9.
go back to reference Campos CM et al (2016) Impact of the everolimus-eluting bioresorbable scaffold in coronary atherosclerosis. Rev Esp Cardiol (Engl Ed) 69(2):109–116CrossRef Campos CM et al (2016) Impact of the everolimus-eluting bioresorbable scaffold in coronary atherosclerosis. Rev Esp Cardiol (Engl Ed) 69(2):109–116CrossRef
10.
go back to reference Mintz GS et al (2011) Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention 6(9):1123–1130CrossRefPubMed Mintz GS et al (2011) Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention 6(9):1123–1130CrossRefPubMed
11.
go back to reference Diletti R et al (2011) Assessment of coronary atherosclerosis progression and regression at bifurcations using combined IVUS and OCT. JACC Cardiovasc Imaging 4(7):774–780CrossRefPubMed Diletti R et al (2011) Assessment of coronary atherosclerosis progression and regression at bifurcations using combined IVUS and OCT. JACC Cardiovasc Imaging 4(7):774–780CrossRefPubMed
12.
go back to reference Muramatsu T et al (2015) Reproducibility of intravascular ultrasound radiofrequency data analysis (virtual histology) with a 45-MHz rotational imaging catheter in ex vivo human coronary arteries. J Cardiol 65(2):134–142CrossRefPubMed Muramatsu T et al (2015) Reproducibility of intravascular ultrasound radiofrequency data analysis (virtual histology) with a 45-MHz rotational imaging catheter in ex vivo human coronary arteries. J Cardiol 65(2):134–142CrossRefPubMed
13.
go back to reference Gutierrez-Chico JL et al (2012) Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. Int J Cardiovasc Imaging 28(3):467–478CrossRefPubMed Gutierrez-Chico JL et al (2012) Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. Int J Cardiovasc Imaging 28(3):467–478CrossRefPubMed
14.
go back to reference Nissen SE et al (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17):2292–2300CrossRefPubMed Nissen SE et al (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17):2292–2300CrossRefPubMed
15.
go back to reference Garcia-Garcia HM et al (2009) Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention 5(2):177–189CrossRefPubMed Garcia-Garcia HM et al (2009) Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention 5(2):177–189CrossRefPubMed
16.
go back to reference Brugaletta S et al (2011) Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging 27(6):859–866CrossRefPubMed Brugaletta S et al (2011) Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging 27(6):859–866CrossRefPubMed
17.
go back to reference Schartl M et al (2001) Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104(4):387–392CrossRefPubMed Schartl M et al (2001) Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104(4):387–392CrossRefPubMed
18.
go back to reference Rasheed Q et al (1995) Intracoronary ultrasound-defined plaque composition: computer-aided plaque characterization and correlation with histologic samples obtained during directional coronary atherectomy. Am Heart J 129(4):631–637CrossRefPubMed Rasheed Q et al (1995) Intracoronary ultrasound-defined plaque composition: computer-aided plaque characterization and correlation with histologic samples obtained during directional coronary atherectomy. Am Heart J 129(4):631–637CrossRefPubMed
19.
go back to reference Campos CM et al (2015) Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12–18, 24-, 30-, 36- and 42-month follow-up in a porcine model. Int J Cardiovasc Imaging 31(3):471–482CrossRefPubMedPubMedCentral Campos CM et al (2015) Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12–18, 24-, 30-, 36- and 42-month follow-up in a porcine model. Int J Cardiovasc Imaging 31(3):471–482CrossRefPubMedPubMedCentral
20.
go back to reference Garcia-Garcia HM et al (2009) Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention 4(4):443–448CrossRefPubMed Garcia-Garcia HM et al (2009) Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention 4(4):443–448CrossRefPubMed
21.
go back to reference Serruys PW et al (2010) Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122(22):2301–2312CrossRefPubMed Serruys PW et al (2010) Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122(22):2301–2312CrossRefPubMed
22.
go back to reference Ormiston JA et al (2012) First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 5(5):620–632CrossRefPubMed Ormiston JA et al (2012) First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 5(5):620–632CrossRefPubMed
23.
go back to reference Bourantas CV et al (2016) Hybrid intravascular imaging: recent advances, technical considerations, and current applications in the study of plaque pathophysiology. Eur Heart J. doi:10.1093/eurheartj/ehw097 Bourantas CV et al (2016) Hybrid intravascular imaging: recent advances, technical considerations, and current applications in the study of plaque pathophysiology. Eur Heart J. doi:10.​1093/​eurheartj/​ehw097
Metadata
Title
Comparative assessment of “plaque/media” change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study
Authors
Yaping Zeng
Rafael Cavalcante
Erhan Tenekecioglu
Pannipa Suwannasom
Yohei Sotomi
Carlos Collet
Mahammad Abdelghani
Hans Jonker
Franck Digne
Dieter Horstkotte
Manfred Zehender
Ciro Indolfi
Francesco Saia
Rosario Fiorilli
Bernard Chevalier
Leonardo Bolognese
Javier Goicolea
Shaoping Nie
Yoshinobu Onuma
Patrick W. Serruys
On behalf of the investigators of Absorb II study
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
The International Journal of Cardiovascular Imaging / Issue 4/2017
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-016-1033-7

Other articles of this Issue 4/2017

The International Journal of Cardiovascular Imaging 4/2017 Go to the issue